Comparative Pharmacology
Head-to-head clinical analysis: METHAZOLAMIDE versus TRUSOPT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHAZOLAMIDE versus TRUSOPT.
METHAZOLAMIDE vs TRUSOPT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbonic anhydrase inhibitor; reduces aqueous humor secretion by inhibiting carbonic anhydrase in ciliary processes, decreasing intraocular pressure.
Carbonic anhydrase inhibitor; decreases aqueous humor secretion by inhibiting carbonic anhydrase in the ciliary processes of the eye.
Oral: 50-100 mg two to three times daily.
One drop of 2% solution in affected eye(s) twice daily, approximately 12 hours apart.
None Documented
None Documented
Terminal half-life: 14-20 hours; approximately 15 hours in adults, prolonged in renal impairment
Clinical Note
moderateMethazolamide + Etacrynic acid
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Etacrynic acid."
Clinical Note
moderateMethazolamide + Bumetanide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Bumetanide."
Clinical Note
moderateMethazolamide + Hydrochlorothiazide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Hydrochlorothiazide."
Clinical Note
moderateTerminal elimination half-life of dorzolamide in whole blood is approximately 4 months due to tight binding to carbonic anhydrase in red blood cells; however, the drug's clinical effect on intraocular pressure has a half-life of about 24 hours.
Renal: 70-90% as unchanged drug; minor biliary/fecal (<10%)
Renal excretion as unchanged drug: approximately 70% of a topically applied dose is excreted renally; the remainder is eliminated via biliary/fecal routes (30%). Following oral administration, renal excretion accounts for about 65-70%.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
Methazolamide + Indapamide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Indapamide."